<!DOCTYPE html>
<html lang="en-us">
  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    
    <title>Overall survival of cHL patients who progress after autologous stem cell transplant: results in novel agent era | Fallingstar Daily R</title>
    <link rel="stylesheet" href="/css/style.css" />
    <link rel="stylesheet" href="/css/fonts.css" />
    <link href="//cdn.bootcss.com/highlight.js/9.12.0/styles/github.min.css" rel="stylesheet">

  </head>

  <body class="page">
    <nav class="header">
      <div class="banner">
<a href="/" class="text">
&Ffr;&Afr;&Lfr;&Lfr;&Ifr;&Nfr;&Gfr;&Sfr;&Tfr;&Afr;&Rfr; &Dfr;&Afr;&Ifr;&Lfr;&Yfr; &Rfr;
</a>
</div>

      <div class="head-meta">
      
        <span><a href="/">&larr; Back to Home</a></span>
        <span class="date">2023-09-20</span>
        
        
        
          
        
        
        <span><a href="https://github.com/rainoffallingstar/daily-rss/edit/master/content/post/pubmed-ncbi-nlm-nih-gov-37729621-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1rkszs2hvz2rhp33oibanfew6vk-lzjjwtd4gwmllk8b-wcceh-fc-20220923065203-ff-20230921190649-v-2-17-9-post6-.md">Edit this page &rarr;</a></span>
        
        
      
      </div>
    </nav>

<div class="container">
<article>
<div class="article-meta">

  <div class="categories">
  
  </div>

  <h1><span class="title">Overall survival of cHL patients who progress after autologous stem cell transplant: results in novel agent era</span></h1>

  

  
  

</div>



<main>
<p>In pre-novel agent era, median post progression overall survival (PPS) of classic Hodgkin lymphoma (cHL) patients (pts) who progress after ASCT have been 2-3 years. Recently, Checkpoint inhibitors (CPI) and brentuximab vedotin (BV) have improved depth and durability of response in this population. Here we report estimate of PPS in pts with relapsed cHL after ASCT in the era of CPI and BV. In this multicenter retrospective study of 15 participating institutions, adult pts with relapsed cHL &hellip;</p>

<script>
var url = "https://pubmed.ncbi.nlm.nih.gov/37729621/?utm_source=curl\u0026utm_medium=rss\u0026utm_campaign=pubmed-2\u0026utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh\u0026fc=20220923065203\u0026ff=20230921190649\u0026v=2.17.9.post6+86293ac";
var strReg = "http|https";
var re = new RegExp(strReg);
setTimeout(function() { if(re.test(url)) {window.location.href = url} }, 10000);
</script>
</main>




<nav class="post-nav">
  <span class="nav-prev"><a href="/post/pubmed-ncbi-nlm-nih-gov-37729615-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1rkszs2hvz2rhp33oibanfew6vk-lzjjwtd4gwmllk8b-wcceh-fc-20220923065203-ff-20230921190649-v-2-17-9-post6-/">&larr; CBFA2T3::GLIS2 Pediatric Acute Megakaryoblastic Leukemia is Sensitive to BCL-XL Inhibition by Navitoclax and DT2216</a></span>
  <span class="nav-next"><a href="/post/pubmed-ncbi-nlm-nih-gov-37730511-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20230921191728-v-2-17-9-post6-/">Implementing standardized diversity, equity, and inclusion approaches within scientific communities &rarr;</a></span>
</nav>




</article>
</div>

<script async src="//yihui.name/js/center-img.js"></script>

<footer>

<div class="footer">
  <ul class="menu">
    
    <li><a href="/"><span data-hover="Home">Home</span></a></li>
    
    <li><a href="/about/"><span data-hover="About">About</span></a></li>
    
    <li><a href="/archives/"><span data-hover="Archive">Archive</span></a></li>
    
    <li><a href="/contributor/"><span data-hover="Contributor">Contributor</span></a></li>
    
    <li><a href="/index.xml"><span data-hover="Subscribe">Subscribe</span></a></li>
    
  </ul>
  
  <div class="copyright">Â© <a href="https://rainoffallingstar.github.io">Fallingstar</a> 2023 | <a href="https://github.com/rainoffallingstar">Github</a></div>
  
</div>
</footer>







</body>
</html>

